Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

07/13/2026, 1:00 PM • GlobeNewswire

Cue Biopharma Announces $50.0 Million Private Placement

Cue Biopharma secured $50 million in funding through a private placement led by Cormorant Asset Management and Columbia Threadneedle Investments. The company will use proceeds to advance clinical development of its immunological disorder therapies, including Phase 2 data expected from a CSU study in China by Q3 2026.

07/09/2026, 9:40 PM • GlobeNewswire

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma granted inducement equity awards to seven new employees on May 3, 2026, including newly appointed President and CEO Shao-Lee Lin, M.D., Ph.D. Dr. Lin received stock options for 655,074 shares and 327,537 restricted stock units, while six other new employees received aggregate options for 518,599 shares and 327,534 RSUs, all at an exercise price of $30.42 per share.

05/07/2026, 7:07 PM • GlobeNewswire

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma announced it will receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim following the selection and approval of the first compound for lead optimization under their collaboration agreement. The company is eligible for up to $337.5 million in additional milestone and royalty payments. Cue Biopharma continues advancing its lead autoimmune asset CUE-401 toward clinical development.

04/08/2026, 8:00 AM • GlobeNewswire

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.

07/23/2025, 9:26 AM • Benzinga

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

Cue Biopharma received positive feedback from the FDA on its pre-IND briefing document for CUE-401, a first-in-class bispecific molecule designed to induce and expand regulatory T cells for the treatment of autoimmune diseases. The company plans to file an IND for CUE-401 after completing final enabling studies.

06/24/2025, 4:48 PM • GlobeNewswire